CrkL antibody (AA 286-303)
Quick Overview for CrkL antibody (AA 286-303) (ABIN3029484)
Target
See all CrkL (CRKL) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 286-303
-
Purpose
- CrkL Antibody / Crk-like protein
-
Purification
- Antigen affinity
-
Immunogen
- Amino acids 286-303 (FPFTHVKIFDPQNPDENE-human) were used as the immunogen for this CrkL antibody.
-
Isotype
- IgG
-
-
-
-
Application Notes
- The stated application concentrations are suggested starting amounts. Titration of the CrkL antibody may be required due to differences in protocols and secondary/substrate sensitivity.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- After reconstitution, the CrkL antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- CrkL (CRKL) (V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like (CRKL))
-
Alternative Name
- CrkL
-
Background
- V-Crk sarcoma virus CT10 oncogene homolog(avian)-like), also called CrkL, encodes a 303-amino acid polypeptide with a predicted molecular mass of ~36 kD. While CrkL is not the human homolog of CRK, it is similar to protein-tyrosine kinases with SH2 and SH3 (src homology) domains. By fluorescence in situ hybridization,the gene is localized to chromosome 22q11, centromeric of the chronic myelogenous leukemia breakpoint region. Senechal et al.(1996)showed that CRKL becomes phosphorylated when overexpressed, activates Ras-dependent and JNK pathways, and transforms fibroblasts. The authors also found CrkL to be a substrate for the BCR-ABL tyrosine kinase, leading them to conclude that it is a tyrosine kinase and an oncogene. CrkLwas required for normal cellular responses to Fgf8, including survival and migration, Erk activation, and target gene expression.
-
UniProt
- P46109
-
Pathways
- Interferon-gamma Pathway, Neurotrophin Signaling Pathway, Signaling of Hepatocyte Growth Factor Receptor
Target
-